Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial
In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.
Asset / Drug
Drug and asset intelligence for retatrutide with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Triple Agonist
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.